<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0" xml:base="http://investors.amgen.com/">
  <channel>
    <title>Amgen Inc. News Releases</title>
    <link>http://investors.amgen.com/</link>
    <description>Amgen Inc. News Releases</description>
    <language>en</language>
    
    <item>
  <title>Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/sports-anchor-and-multiple-myeloma-patient-rod-gilmore-joins</link>
  <description>Updated Tool for 2019 Helps Patients Create Their Most Valuable Plan for Managing Multiple Myeloma Gilmore Joins Baseball Hall of Famer Dave Winfield and Don Baylor Jr. Who Honor the Late Don Baylor's Legacy by Raising Awareness of Multiple Myeloma THOUSAND OAKS, Calif. , Oct.</description>
  <pubDate>Tue, 15 Oct 2019 09:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">29041</guid>
    </item>
<item>
  <title>Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-foundation-launches-amgen-biotech-experience-pittsburgh</link>
  <description>Unique Partnership With the Richard King Mellon Foundation Brings Renowned Science Education Program to Pittsburgh Area High School Students   The Citizen Science Lab Will Serve as Local Program Site     THOUSAND OAKS, Calif. and PITTSBURGH , Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today</description>
  <pubDate>Wed, 09 Oct 2019 09:05:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">29036</guid>
    </item>
<item>
  <title>Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-announces-new-clinical-data-evaluating-novel-0</link>
  <description>Responses Seen in Multiple Tumor Types With KRAS G12C Mutation     THOUSAND OAKS, Calif. , Sept. 27, 2019 /PRNewswire/ --  Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C -mutant solid tumors.</description>
  <pubDate>Sat, 28 Sep 2019 01:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">29026</guid>
    </item>
<item>
  <title>Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/heart-attack-survivors-are-taking-steps-reduce-their</link>
  <description>This World Heart Day, Amgen is Releasing Results of a Global Survey of 3,200 Heart Attack Survivors Conducted Across 13 Countries   Close to Half of Survivors Are Not Monitoring Their Cholesterol Regularly     THOUSAND OAKS, Calif. , Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day</description>
  <pubDate>Thu, 26 Sep 2019 09:02:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">29016</guid>
    </item>
<item>
  <title>Amgen To Webcast Investor Call At ESMO 2019</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-webcast-investor-call-esmo-2019</link>
  <description>  THOUSAND OAKS, Calif. , Sept. 25, 2019 /PRNewswire/ --  Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology ( ESMO ) 2019 Congress on Saturday, Sept. 28 , at 10 a.m. PT . David M.</description>
  <pubDate>Wed, 25 Sep 2019 16:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">29006</guid>
    </item>
<item>
  <title>Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-results-two-phase-3-blincytor</link>
  <description>Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy     THOUSAND OAKS, Calif. , Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label,</description>
  <pubDate>Tue, 24 Sep 2019 16:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">28986</guid>
    </item>
<item>
  <title>Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-showcases-new-data-oncology-pipeline-and-portfolio-esmo</link>
  <description>New Data Show Clinical Responses in Colorectal and Appendiceal Cancer Patients Treated With AMG 510 Two Late-Breaking Abstracts With Data Highlighting IMLYGIC® (Talimogene Laherparepvec) for Neoadjuvant Melanoma and in Combination for Advanced Melanoma Results From Studies Across Marketed Portfolio</description>
  <pubDate>Tue, 17 Sep 2019 16:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">28981</guid>
    </item>
<item>
  <title>Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-present-bank-america-merrill-lynch-global-healthcare-8</link>
  <description>THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ --  Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019 , in London . David W. Meline , executive vice president and chief financial</description>
  <pubDate>Fri, 13 Sep 2019 16:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">28971</guid>
    </item>
<item>
  <title>Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-announces-phase-3-candor-study-combining-kyprolisr</link>
  <description>First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ --  Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS ® (carfilzomib) in combination with</description>
  <pubDate>Fri, 13 Sep 2019 09:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">28961</guid>
    </item>
<item>
  <title>Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019</title>
  <link>http://investors.amgen.com/news-releases/news-release-details/amgen-highlights-new-data-kyprolisr-carfilzomib-and-oncology</link>
  <description>Data Presented From Anti-BCMA BiTE® and MCL-1 Programs KYPROLIS Data Examine More Convenient Once-Weekly Dosing Regimen and Include Additional Phase 3 Results THOUSAND OAKS, Calif. , Sept. 12, 2019 /PRNewswire/ --  Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and</description>
  <pubDate>Thu, 12 Sep 2019 09:00:00 -0400</pubDate>
    <dc:creator>Amgen Inc. News Releases</dc:creator>
    <guid isPermaLink="false">28956</guid>
    </item>

  </channel>
</rss>
